Tuberculosis-focused capacity building

Eli Lilly is undertaking a range of capacity building projects in India focused on tuberculosis.

Summary  

  • What: Eli Lilly is undertaking a range of technology-based projects in India to build local capacity to effectively diagnose, treat and follow up with tuberculosis patients.
  • Context: The projects are part of Eli Lilly’s MDR-TB Partnership, which aims to build health worker capacity and ensure access to quality multidrug-resistant tuberculosis medicines.
  • Details: Eli Lilly has supported projects in several areas in India, including Jharkhand and Hyderabad.
  • Change: Pilots are now being scaled up, following positive impact assessments.

Looking closer

Eli Lilly is undertaking a range of innovative technology-based projects in India to build local capacity to effectively diagnose, treat and follow up with tuberculosis patients, through its MDR-TB Partnership. The Lilly MDR-TB Partnership has run since 2003.

Two notable examples are:

1) Development of a mobile application to support health care providers in rural areas to facilitate identification, referral and tracking of patients with pulmonary tuberculosis. This pilot ran from 2013-2015 in Jharkhand in eastern India.

2) Development of a web-based tool to improve case notification to India’s National Tuberculosis Control Programme and treatment adherence of patients treated by private sector health services. This pilot ran in 2015 in Hyderabad in southern India.

The outcomes of both pilot interventions were measured and demonstrated positive results. Both are now being scaled up. For the first example, the project has been expanded to additional areas in Jharkhand and Uttar Pradesh in northern India. For the second example, components of the project will be scaled up to other health services across India, with support from the Global Fund.

While some companies measured in the Access to Medicine Index 2016 have implemented or supported innovative technology-based interventions aiming to address specific disease areas, the two examples provided demonstrate Eli Lilly’s more comprehensive and multi-pronged approach to building skills and capacities needed to effectively address a high-burden disease, tuberculosis, in different areas and sectors.

Sign up to receive updates about our work.